Company presentation

Brussels

February, 2016



FORWARD-LOOKING STATEMENTS

This document and the accompanying oral presentation contain information on Bone Therapeutics SA' markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from Bone Therapeutics SA own estimates. Investors should not base their investment decision on this information. This document and the accompanying oral presentation also contain certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analysis of estimates not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future.

Bone Therapeutics SA draws your attention to the fact that forward-looking statements cannot under any circumstance be construed as a guarantee of the Company's future performance and that the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates may differ materially from those proposed or reflected in the forward-looking statements contained in this document and the accompanying oral presentation. Furthermore, even if Bone Therapeutics SA financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document and the accompanying oral presentation, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. Certain figures and numbers appearing in this document and the accompanying oral presentation and percentages appearing in the tables are therefore not necessarily equal to the sum of the individually rounded figures, amounts or percentages.



AGENDA

- ► Welcome and introduction
- Operational highlights
- Corporate and financial highlights
- ► News flow

A&Q



KEY HIGHLIGHTS OF 2015


	Important advancements in the Phase II proof-of-concept trials
	ALLOB [®] Phase I/IIA delayed-union trial
	 Positive efficacy results in first patient cohort
Pipeline	 Treated second patient cohort without safety concerns
Fipeline	 Initiated new Phase IIA trial to extend delayed-union program to multiple fractures
	Safety results in ALLOB [®] Phase IIA spinal fusion trial
	Initiated novel Phase IIA trial for ALLOB [®] in rescue spinal fusion
	First results from PREOB [®] Phase IIA severe osteoporosis trial
	Established a US subsidiary in Boston
Corporate	Opened new headquarters at the Gosselies Biopark
	 Strengthened the Board of Directors and management team
Financial	Successful €37M IPO on Euronext Brussels and Euronext Paris
	Cash position at end of December 2015 of €33.6M*
	Awarded €5M in funding from the Walloon Region in 2015

*Unaudited



A GAME CHANGER IN ORTHOPAEDICS

Rationale for bone cell therapy in orthopaedics and bone diseases




Skeleton: a naturally regenerative system

Limitations of standard orthopaedic approaches



Minimally invasive administration





Bone Therapeutics

*Only lumbar spine fusion procedures



Two products: autologous (PREOB®) & allogeneic (ALLOB®) in six indications

Indication	Platform	Preclinical	Phase I/IIA	Phase IIB/III
Non-Unions	PREOB ®			
Delayed-Unions and Multiple Fractures	ALLOB ®			
Spinal Fusion	ALLOB ®			
Rescue Spinal Fusion	ALLOB ®			
Osteonecrosis	PREOB®			
Osteoporosis	PREOB®			





2015 HIGHLIGHTS



NEW OPPORTUNITIES IN ORTHOPAEDICS – SPINAL FUSION

- Orthopaedics market characterized by:
 - Large & growing market (~4% p.a.)
 - · Limited innovation & high unmet medical need
- Bone Therapeutics' innovative bone-forming cell therapies can potentially enhance current treatments
- Seizing the opportunity in spinal fusion (18% of orthopaedics market)
 - Characterized by strong growth (5-6% p.a.) and large unmet need
 - · Current standard-of-care applied with limited success
 - Up to 25% of patients unsatisfied with their surgery
- Creating a market in spinal fusion
 - Now in Phase IIA trials with ALLOB®
 - No safety issues so far and first efficacy results due






PHASE IIA ALLOB® SPINAL FUSION TRIAL

1,000,000 surgeries p.a. in EU & US, of which 500,000 at lumbar level Slow progression to fusion and treatment failure (no fusion) in 5% to 35% of procedures Declining sales of Infuse (BMP2) – FDA warning and safety concerns

- Phase IIA proof-of-concept
- 16 patients with symptomatic
 lumbar degenerative disc disease,
 requiring a spinal fusion procedure
- Objectives: safety & efficacy (functional disability and fusion)
- Duration: 12 months follow-up



pre-op

1 year post-op

4 years post-op



PHASE IIA ALLOB® SPINAL FUSION TRIAL

Local administration of ALLOB® intended to promote faster & better bone formation in lumbar interbody fusion





- Standard-of-care surgical approach combining cage and bioceramic granules/ALLOB[®] mix
- Single application (add-on to standard-of-care)
- ► 75% of patients treated
- ► No safety issues reported


Next steps Efficacy results of first 4 patients and completion of recruitment



PHASE IIA ALLOB® RESCUE SPINAL FUSION TRIAL

Up to 25% failure after initial spinal fusion surgery with non-union and persistent pain Standard-of-care revision surgery: open, additional difficulties and associated with complications

- Phase IIA, open, multicentre, proof-of-concept
- Single minimally invasive (percutaneous) implantation into the failed fusion site
- 16 patients with a failed lumbar spinal fusion
 (15 months after the initial fusion procedure)
- 12-month study follow-up
- Study endpoints: clinical symptoms (pain & disability) and radiological healing




Next step Interim safety results of first 4 patients



PHASE I/IIA ALLOB® DELAYED-UNION TRIAL

- Open continuous follow-up of safety and efficacy
- Single percutaneous implantation of ALLOB[®] into delayed-union site
- Positive results from first cohort - All 4 patients met primary endpoints within 6 months
- Second cohort of patients treated without safety issues




Next steps Interim efficacy results of first 8 patients & safety results of first 12 patients



PHASE IIA PREOB® OSTEOPOROSIS TRIAL

- Phase IIA proof-of-concept
- Patients suffering from severe osteoporosis not responding to antiosteoporotic treatment (i.e., losing bone mass)
- Objectives: to determine (i) the body distribution of PREOB[®] after intravenous infusion and (ii) the effect on bone markers
- 20 patients; 12-month follow-up
- 8 patients included
- No treatment-related safety concerns reported



Next step Efficacy results of first patient cohort (8 patients)

CORPORATE HIGHLIGHTS 2015

Established a US subsidiary

- Bone Therapeutics USA Inc., in Boston, Massachusetts
- First step in the development of its US clinical trials program
- Approval US clinical trials by the end of 2016

Opened new headquarters at the Gosselies Biopark

- Administrative and R&D departments have now moved to the new facilities
- Production activities to be transferred start of 2017 after obtaining GMP accreditation
- State-of-the art production facility will secure first commercial cell therapy production capacity and ensure continued growth of the Company

Strengthened management team

Thomas Lienard appointed as Chief Business Officer





FINANCIAL HIGHLIGHTS 2015

- ► Cash position on 31 December, 2015 of €33.6 million
 - Well in line with company expectations
- ► €5 million funding granted by the Walloon Region in 2015
 - Equals 13.5% of IPO proceeds
- Full Annual Results 2015 on 14 April 2016





NEWS FLOW 2016



UPCOMING CLINICAL NEWS

Indication	Phase	Platform	Actions	Q1	2015 Q2	Q3	Q4	Q1 (2(016 Q3	Q4	Q1	20 Q2	17 Q3	Q4
Non-Union	IIB/III	PREOB®	Study status for Interim/DSMB Launch of US clinical trial												
Delayed-Union	I/IIA	ALLOB®	Efficacy 4 patients Safety 8 patients Efficacy 8 patients Safety 12 patients Efficacy 12 patients	✓	•			1							
Spinal Fusion	IIA	ALLOB [®]	Safety 4 patients Safety 8 patients Safety 12 patients Efficacy 4 patients Efficacy 8 patients												
Revision Spinal Fusion	IIA	ALLOB®	Initiation of study Safety 4 patients Safety 8 patients Efficacy 4 patients		1										
Osteonecrosis	Ш	PREOB [®]	Site update Study status for Interim/DSMB Launch of US clinical trial												
Osteoporosis	IIA	PREOB®	Safety 8 patients Efficacy 8 patients Safety 16 patients												





Q&A



19 BONE THERAPEUTICS – February 2016

CONTACT

Enrico BASTIANELLI, MD, MBA

Chief Executive Officer

Wim GOEMAERE, MAE

Chief Financial Officer

Phone: +32 (0)2 529 59 90 Fax: +32 (0)2 529 59 93

E-mail address: info@bonetherapeutics.com Postal address: Rue Auguste Piccard 37, 6041 Gosselies

Website: www.bonetherapeutics.com



